ArticleDiscover oncology2026
Causal effects of drug exposure on gastric cancer risk: a Mendelian randomization study involving 23 commonly used medications in the European population.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrevious studies have indicated potential associations between some drugs and cancer risk, but the causal relationship with gastric cancer remains unclear. This study aimed to explore the causality between 23 medications and gastric cancer using Mendelian randomization (MR) analysis.
methodsA two-sample MR analysis was conducted to assess the causal effects of medications on gastric cancer risk. Primary causal estimates were derived using the inverse variance weighted method, complemented by weighted median, MR-Egger, simple mode, and weighted mode methods. Sensitivity analyses (MR-PRESSO, MR-Egger regression, Cochran's Q test, leave-one-out analysis, Steiger filtering) validated the robustness of significant findings. Furthermore, enrichment analysis was used to analyze the biological functions of medication-related genes.
resultsAfter Bonferroni correction, anti-migraine formulations (OR, 0.83 [95% CI, 0.70-0.98]; p = 0.0253), drugs acting on the renin-angiotensin system (OR, 0.83 [95% CI, 0.73-0.94]; p = 0.0035), and adrenergic drugs/inhalants (OR, 0.86 [95% CI, 0.76-0.98]; p = 0.0212) were found to be suggestively associated with a reduced risk of gastric cancer in European populations. Sensitivity analyses revealed no significant heterogeneity or horizontal pleiotropy (all p > 0.05), and the Steiger filtering excluded reverse causality-related bias, collectively supporting the robustness of the primary findings. No significant causal relationship was found between the remaining 20 medications and gastric cancer risk. The causal association between 23 medications and gastric cancer differed between East Asian and European populations, indicating that the applicability of the causalities to non-European populations remains limited.
conclusionThis study revealed negative genetically proxied associations related to drug targets of anti-migraine formulations, drugs acting on the renin-angiotensin system, and adrenergic drugs/inhalants with gastric cancer risk. These hypothesis-generating findings may help inform future mechanistic and clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.